Ensifentrine for COVID-19: real-time analysis

Download Image

Post

c19early.org

Ensifentrine for COVID-19

1 study with 45 patients

Serious outcome risk

Ensifentrine

Control

No significant improvements are seen in meta-analysis to date.

COVID-19 Ensifentrine studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−150%

Mortality (1)−150%

RCTs (1)−150%

Late (1)−150%

00.511.5+

← Ensifentrine
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}

Ensifentrine is a small-molecule dual PDE3/4 inhibitor with bronchodilator and anti-inflammatory effects.


May 1 2021	MacDonald-Berko et al., NCT04527471	A Single-center, Pilot, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ensifentrine in the Recovery of Hospitalized Patients With COVID-19
May 1 2021	150% higher mortality (p=1) and 150% worse recovery (p=1). RCT 45 hospitalized COVID-19 patients showing no significant difference with ensifentrine treatment.